<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211873</url>
  </required_header>
  <id_info>
    <org_study_id>DGD-44-050</org_study_id>
    <nct_id>NCT01211873</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions</brief_title>
  <acronym>SENTIO</acronym>
  <official_title>Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety (what are the side effects)and efficacy
      (how well does it work) of Dotarem® when used in taking images of the brain / spine. The
      results will be compared to the results of MRI taken without Dotarem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called
      Dotarem®. The purpose of this study is to look at the safety (what are the side effects) and
      efficacy (how well does it work) of Dotarem® when used for taking images of the brain and
      spine. The results of the MRI will be compared to the results of images taken without
      Dotarem®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both &quot;Pre&quot; and &quot;Paired&quot; Evaluation, Each Lesion is Scored With 3-point Scales.</measure>
    <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
    <description>To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization.
Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. &quot;Pre&quot; refers to unenhanced MRI. &quot;PAIRED&quot; refer to combined unenhanced and enhanced MRI.
The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Quality of Images on 3-point Scale: Poor, Fair or Good.</measure>
    <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Diagnostic Confidence on 5-point Scale Ranging From Nil to Excellent With Poor, Moderate and High as Intermediate Grades.</measure>
    <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lesions With MRI Signal Intensity Changes After Contrast Agent Injection.</measure>
    <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability.</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Vital Signs (Supine Systolic and Diastolic Blood Pressures, Pulse).</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure ECG</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection-site Tolerance on the Visual Analog Scale From 0 (no Pain) to 10 (Maximal Pain).</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Blood Sample.</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Diagnostic Self Evaluation</condition>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Dotarem (gadoterate meglumine )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnevist (gadopentetate dimeglumine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dotarem and Magnevist were randomised as 2:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem 2 (gadoterate meglumine )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric patients were assigned to Dotarem group only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem (gadoterate meglumine)</intervention_name>
    <description>0.1 mmol/kg by body weight, single IV injection</description>
    <arm_group_label>Dotarem (gadoterate meglumine )</arm_group_label>
    <arm_group_label>Dotarem 2 (gadoterate meglumine )</arm_group_label>
    <other_name>Dotarem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnevist (gadopentetate dimeglumine)</intervention_name>
    <description>0.1 mmol/kg by body weight, single IV injection</description>
    <arm_group_label>Magnevist (gadopentetate dimeglumine)</arm_group_label>
    <other_name>Magnevist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subject and pediatric subjects (aged greater than or equal to two (2) years).

          -  Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous
             imaging procedure.

          -  Female of childbearing potential patients must have effective contraception
             (contraceptive pill or intra-uterine device) or be surgically sterilized or
             post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine
             pregnancy test within 24 hours prior to study MRI.

          -  Has been fully informed about the study, and has consented to participate.

        Exclusion Criteria:

          -  Having acute or chronic grade IV or V renal insufficiency.

          -  Known class III/IV congestive heart failure.

          -  Suffering from long QT syndrome.

          -  Unstable health condition or circumstances (e.g. suffering from severe
             claustrophobia).

          -  Having any contraindications to MRI such as a pace-maker, magnetic material or any
             other conditions that would preclude proximity to a strong magnetic field.

          -  Known allergy to Gadolinium chelates.

          -  Having received any contrast agent within 3 days prior to study contrast
             administration, or is scheduled to receive any contrast agent within 24 hours after
             the study contrast administration.

          -  Pregnant, breast feeding, or planning to become pregnant during the trial.

          -  Previously participated in this trial.

          -  Having participated within 30 days in another clinical trial involving an
             investigational drug.

          -  Any condition which, based on the investigator's clinical judgement, would prevent the
             patient from completing all trial assessments and visits.

          -  Inability or unwillingness to cooperate with the requirements of this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Maravilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wasington School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, UABMC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University medical center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Imaging</name>
      <address>
        <city>Indian Wells</city>
        <state>California</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Clinical Research, Inc.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Clinical Research Solutions</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocare Center for Research</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gruss Magnetic resonance Research Clinic</name>
      <address>
        <city>NYC</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WestImage - Division of Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45248</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnóstico</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TCBA</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-institut f.Radiodiagnostik</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Tulln</name>
      <address>
        <city>Tulln</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo / UNIFESP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departamento de Neuroradiologia</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurocirugia Dr. Asenjo,</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro- CRHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui De Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologie A - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fédération d'Imagerie Médicale,Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital LMU Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Radiologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroradiologia,II Università Di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Unversity Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo - Serviço de radiologia</name>
      <address>
        <city>Vigo Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Department of Radiology</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <results_first_submitted>July 25, 2013</results_first_submitted>
  <results_first_submitted_qc>April 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2014</results_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNS</keyword>
  <keyword>Contrast Agent</keyword>
  <keyword>MRI</keyword>
  <keyword>Dotarem</keyword>
  <keyword>Magnevist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient First Visit : 16 Sept 2010 Last patient Last Visit : 16 Nov 2011 Locations: radiology departments</recruitment_details>
      <pre_assignment_details>Any patient who did not fulfill eligibility criteria was not randomized / assigned to a treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dotarem (Gadoterate Meglumine )</title>
          <description>Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.</description>
        </group>
        <group group_id="P2">
          <title>Magnevist (Gadopentetate Dimeglumine)</title>
          <description>Dotarem and Magnevist were randomised as 2:1 ratio</description>
        </group>
        <group group_id="P3">
          <title>Dotarem 2 (Gadoterate Meglumine )</title>
          <description>Pediatric patients were assigned to Dotarem group only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnevist (Gadopentetate Dimeglumine)</title>
          <description>adults received Magnevist as 1:2 ratio compared to Dotarem</description>
        </group>
        <group group_id="B2">
          <title>Dotarem (Gadoterate Meglumine )</title>
          <description>adults received Dotarem as 2:1 ratio compared to Magnevist.</description>
        </group>
        <group group_id="B3">
          <title>Dotarem 2 (Gadoterate Meglumine )</title>
          <description>All children were assigned to Dotarem</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.95" spread="14.43"/>
                    <measurement group_id="B2" value="53.17" spread="14.35"/>
                    <measurement group_id="B3" value="9.29" spread="4.49"/>
                    <measurement group_id="B4" value="49.8" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both &quot;Pre&quot; and &quot;Paired&quot; Evaluation, Each Lesion is Scored With 3-point Scales.</title>
        <description>To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization.
Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. &quot;Pre&quot; refers to unenhanced MRI. &quot;PAIRED&quot; refer to combined unenhanced and enhanced MRI.
The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.</description>
        <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
        <population>The primary analysis was performed at the patient level using off-site readings by 3 readers. The number of participants for analysis depended on the number of evaluable cases (pre and paired)determinted by each reader. Only adult participants included in this data set.</population>
        <group_list>
          <group group_id="O1">
            <title>Dotarem (Gadoterate Meglumine ) PRE</title>
            <description>any sequence acquired prior to injection will be pooled as PRE</description>
          </group>
          <group group_id="O2">
            <title>Dotarem (Gadoterate Meglumine ) PAIRED</title>
            <description>all sequences pre and post injection wil be pooled as PAIRED</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both &quot;Pre&quot; and &quot;Paired&quot; Evaluation, Each Lesion is Scored With 3-point Scales.</title>
          <description>To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization.
Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. &quot;Pre&quot; refers to unenhanced MRI. &quot;PAIRED&quot; refer to combined unenhanced and enhanced MRI.
The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.</description>
          <population>The primary analysis was performed at the patient level using off-site readings by 3 readers. The number of participants for analysis depended on the number of evaluable cases (pre and paired)determinted by each reader. Only adult participants included in this data set.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Border Delineation Blinded Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.23"/>
                    <measurement group_id="O2" value="3.30" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Border Delineation Blinded Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.43"/>
                    <measurement group_id="O2" value="4.49" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Border Delineation Blinded Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.29"/>
                    <measurement group_id="O2" value="2.54" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal Morphology Blinded Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.05"/>
                    <measurement group_id="O2" value="3.70" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal Morphology Blinded Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.24"/>
                    <measurement group_id="O2" value="4.49" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal Morphology Blinded Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.13"/>
                    <measurement group_id="O2" value="2.93" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Enhancement Blinded Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.20"/>
                    <measurement group_id="O2" value="3.11" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Enhancement Blinded Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.15"/>
                    <measurement group_id="O2" value="3.73" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Enhancement Blinded Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.13"/>
                    <measurement group_id="O2" value="2.95" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Quality of Images on 3-point Scale: Poor, Fair or Good.</title>
        <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Diagnostic Confidence on 5-point Scale Ranging From Nil to Excellent With Poor, Moderate and High as Intermediate Grades.</title>
        <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lesions With MRI Signal Intensity Changes After Contrast Agent Injection.</title>
        <time_frame>up to 24 hours as the safety is assessed till 24 hours after injection</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability.</title>
        <time_frame>up to 29 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Vital Signs (Supine Systolic and Diastolic Blood Pressures, Pulse).</title>
        <time_frame>up to 24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure ECG</title>
        <time_frame>up to 24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Injection-site Tolerance on the Visual Analog Scale From 0 (no Pain) to 10 (Maximal Pain).</title>
        <time_frame>up to 24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Blood Sample.</title>
        <time_frame>up to 24 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected since the patient signing the patient consent form till the end of the last visits, maximum duration is 29 days.</time_frame>
      <desc>participants at risk were subjects exposed to contrast agent administration. In Dotarem group 240 adults were injected, Dotarem group 2 , 38 children were injected (2 children were withdrawn after agent administration) and in Magnevist group 117 adults were injected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dotarem (Gadoterate Meglumine )</title>
          <description>Dotarem and Magnevist were randomised as 2:1 ratio for adults</description>
        </group>
        <group group_id="E2">
          <title>Magnevist (Gadopentetate Dimeglumine)</title>
          <description>Dotarem and Magnevist were randomised as 2:1 ratio</description>
        </group>
        <group group_id="E3">
          <title>Dotarem 2 (Gadoterate Meglumine )</title>
          <description>children were only assigned to Dotarem</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small intestine perforation</sub_title>
                <description>not related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological decompensation</sub_title>
                <description>not related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <description>not related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>injection site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. The data are the exclusive property of Guerbet.
The investigator undertakes to submit to Guerbet any draft articles or papers related to this study within 30 days of their submission to the scientific review or the congress scientific committee.
All written or oral papers and publications must have the joint agreement of the investigator and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pierre Desché, MD - VP Development, Medical and Regulatory Affairs</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 1 45 91 50 00</phone>
      <email>pierre.desche@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

